• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 10-K/A filed by SS Innovations International Inc.

    3/31/26 9:10:41 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care
    Get the next $SSII alert in real time by email

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 10-K/A

    (Amendment No. 1)

     

    (Mark One)

     

    ☒ ANNUAL REPORT PURSUANT TO SECTIONS 13 OR 15 (d) OF THE

    SECURITIES AND EXCHANGE ACT OF 1934

     

    For the fiscal year ended December 31, 2025

     

    ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    For the transition period from _____________ to _____________

     

    Commission file number: 001-42615

     

    SS INNOVATIONS INTERNATIONAL, INC.

    (Exact name of registrant as specified in its charter)

     

    Florida   47-3478854
    (State or Other Jurisdiction of   (I.R.S. Employer
    Incorporation or Organization)   Identification No.)

     

    405, 3rd  Floor, iLabs Info Technology Centre

    Udyog Vihar, Phase III

    Gurugram, Haryana 122016, India 

    (Address of Principal Executive Offices)

     

    Registrant’s telephone number, including area code: +91 73375 53469

     

    Securities registered under Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   SSII   The Nasdaq Stock Market LLC

     

    Indicate by check mark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act. Yes ☐ No ☒

     

    Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☒

     

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such a shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (ss.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

     

    Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

     

    Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large, accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

     

    Large Accelerated Filer ☐  Accelerated Filer ☐ 
    Non-accelerated filer ☒ Smaller reporting company ☒ 
      Emerging Growth Company ☐  

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

     

    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

     

    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

     

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

     

    State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold, or the average bid and asked prices of such common equity as of the last business day of the registrant’s most recently completed second fiscal quarter: $270,113,872.

     

    The number of shares outstanding of the issuer’s common stock, $0.0001 par value, as of March 9, 2026, was 200,231,535 shares.

     

    DOCUMENTS INCORPORATED BY REFERENCE: No documents are incorporated by reference into this Report except those Exhibits so incorporated as set forth in the Exhibit index.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Amendment No. 1 on Form 10-K/A (this “Form 10-K/A”) to the Annual Report on Form 10-K of SS Innovations International, Inc. (“SSi”, “the Company”, “we”, “our” or “us”) for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 10, 2026 (the “Form 10-K”), is being filed for the purposes of amending Item 15(b) of Part IV of the Form 10-K to include Exhibit 97.1, which was inadvertently omitted in the Form 10-K.

     

    Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), this Form 10-K/A also contains new certifications by the principal executive officer and the principal financial officer as required by Section 302 of the Sarbanes-Oxley Act of 2002. Because no financial statements are included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted.

     

    Except as described above, this Form 10-K/A does not modify or update the disclosures in, or any exhibits to, the Form 10-K. Furthermore, this Form 10-K/A does not change any previously reported financial results, nor does it reflect any events which occurred subsequent to the filing of the Form 10-K. Accordingly, this Amendment should be read in conjunction with our filings with the SEC subsequent to the filing of the Form 10-K. Information not affected by this Form 10-K/A remains unchanged and reflects the disclosures made at the time the Form 10-K was filed.

     

     

     

    TABLE OF CONTENTS

     

        Page
         
    PART IV   1
         
    Item 15. Exhibits and Financial Statement Schedules   1
    Signatures   2

     

    i

     

     

    PART IV

     

    Item 15. Exhibits and Financial Statement Schedules.

     

      (b) Exhibits.

     

    Exhibit
    Number
      Description
    3.1(i)   Amended and Restated Articles of Incorporation(1)
    3.1(ii)   Articles of Amendment to Amended and Restated Articles of Incorporation(2)
    3.2   By-Laws(1)
    10.1   2016 Incentive Stock Plan(1)+
    10.2    Employment Agreement with Dr. Sudhir Srivastava(3)+
    10.3   Employment Agreement with Dr. Vishwajyoti P. Srivastava(3)+
    10.4   Employment Agreement with Barry F. Cohen(3)+
    10.5   Services Agreement with Milan Rao (4)+
    10.6   Form of Director Appointment Agreement(1)+
        Form of Indemnification Agreement(1)+
    10.7   Form of Indemnification Agreement(1)+
    10.8   Offer Letter and Sanction Letter with HDFC Bank(3)
    14.1   Code of Ethical Conduct(1)
    14.2   Insider Trading Policy(5)
    21.1     List of Subsidiaries(5)
    23.1   Consent of BDO India Services Private Limited§
    31.1   Section 302 Certification by Chief Executive Officer§
    31.2   Section 302 Certification by Chief Financial Officer§
    31.3   Section 302 Certification by Chief Executive Officer(6)
    31.4   Section 302 Certification by Chief Financial Officer(6)
    32.1   Section 906 Certification by Chief Executive Officer§
    32.2   Section 906 Certification by Chief Financial Officer§
    97.1   Clawback Policy(6)
    99.1   Audit Committee Charter(5)
    99.2   Compensation Committee Charter(5)
    99.3   Nominating and Corporate Governance Committee Charter(5)
    101.INS   Inline XBRL Instance Document.§
    101.SCH   Inline XBRL Taxonomy Extension Schema Document.§ 
    101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.§
    101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.§
    101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.§
    101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.§
    104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).§

      

    (1) Filed as an exhibit to the Company’s Registration Statement on Form S-1 (File No. 333-216054) and incorporated herein by reference.

     

    (2) Filed as an exhibit to the Company’s Current Report on Form 8-K filed on April 19, 2023, and incorporated herein by reference.

     

    (3) Filed as an exhibit to the Company’s Registration Statement on Form S-1 (File No. 333-293114) and incorporated herein by reference.

     

    (4) Filed as an exhibit to the Company’s Current Report on Form 8-K, filed on January 8, 2026, and incorporated herein by reference.

     

    (5) Filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on April 15, 2025, and incorporated herein by reference.

     

    (6) Filed herewith.

     

    + Indicates management contract or compensatory plan or arrangement.
       
    § Previously filed or furnished with the Form 10-K.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      SS INNOVATIONS INTERNATIONAL, INC.
         
    Dated: March 31, 2026 By: /s/ Sudhir Prem Srivastava
        Sudhir Prem Srivastava, M.D.
        Chairman and Chief Executive Officer
        (Principal Executive Officer)

     

    Dated: March 31, 2026 By: /s/ Milan Rao
        Milan Rao
        Global Chief Operating Officer
        And Chief Financial Officer

     

    2

     

    0001676163 true FY 0001676163 2025-01-01 2025-12-31 0001676163 2025-06-30 0001676163 2026-03-09 iso4217:USD xbrli:shares
    Get the next $SSII alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SSII

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SSII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SS Innovations Expands Global Opportunity with Regulatory Approval of the SSi Mantra Surgical Robotic System in Colombia, Oman, Sri Lanka and Kenya

    FORT LAUDERDALE, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company has received regulatory approval for the SSi Mantra surgical robotic system (the "SSi Mantra"), for multiple indications in Colombia, Oman, Sri Lanka and Kenya. The Company received regulatory approval for the SSi Mantra from the Instituto Nacional de Vigilancia de Medicamentos y Alimentos ("INVIMA") in Colombia in November 2025, from the Directorate General of Pharmaceutical

    3/30/26 8:30:00 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    SS Innovations' SSi Mantra Surgical Robotic System Approved for Telesurgeries in Indonesia and the Philippines

    FORT LAUDERDALE, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company's SSi Mantra surgical robotic system has been approved for telesurgeries in Indonesia and the Philippines. The Company today also announced that more than 150 cumulative telesurgeries have been successfully performed utilizing the SSi Mantra surgical robotic system, primarily in India. Among recent highlights showcasing the advanced capabilities of the SSi Mantra, a total of

    3/18/26 8:30:00 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    SS Innovations Reports Fourth Quarter and Full Year 2025 Financial Results

    FORT LAUDERDALE, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and twelve months ended December 31, 2025. The Company also filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the Securities and Exchange Commission on March 10, 2026. Fourth Quarter 2025 Overview Revenue increased 79.1% to $14.5 million from $8.1 million in the fourth quarter of 2024.Gross margin of 43.9% compared to 48

    3/10/26 8:30:00 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    $SSII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sudhir Srivastava

    4 - SS Innovations International, Inc. (0001676163) (Issuer)

    3/27/26 8:05:26 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    Director Adams Timothy P. bought $1,197,000 worth of shares (300,000 units at $3.99) (SEC Form 4)

    4 - SS Innovations International, Inc. (0001676163) (Issuer)

    3/10/26 6:04:41 PM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by SS Innovations International Inc.

    4 - SS Innovations International, Inc. (0001676163) (Issuer)

    3/10/26 6:03:34 PM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    $SSII
    SEC Filings

    View All

    Amendment: SEC Form 10-K/A filed by SS Innovations International Inc.

    10-K/A - SS Innovations International, Inc. (0001676163) (Filer)

    3/31/26 9:10:41 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    SS Innovations International Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - SS Innovations International, Inc. (0001676163) (Filer)

    3/30/26 8:30:17 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    SEC Form D filed by SS Innovations International Inc.

    D - SS Innovations International, Inc. (0001676163) (Filer)

    3/19/26 4:05:20 PM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    $SSII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Adams Timothy P. bought $1,197,000 worth of shares (300,000 units at $3.99) (SEC Form 4)

    4 - SS Innovations International, Inc. (0001676163) (Issuer)

    3/10/26 6:04:41 PM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    Director Moll Frederic H bought $1,999,999 worth of shares (501,253 units at $3.99), increasing direct ownership by 5% to 10,775,485 units (SEC Form 4)

    4 - SS Innovations International, Inc. (0001676163) (Issuer)

    3/10/26 6:05:34 PM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    Amendment: COO - Americas Cohen Barry F bought $3,799 worth of shares (426 units at $8.92), increasing direct ownership by 0.00% to 8,866,888 units (SEC Form 4)

    4/A - SS Innovations International, Inc. (0001676163) (Issuer)

    6/30/25 6:55:24 PM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    $SSII
    Leadership Updates

    Live Leadership Updates

    View All

    SS Innovations Appoints Milan Rao as Global Chief Operating Officer and Chief Financial Officer

    FORT LAUDERDALE, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Milan Rao as the Company's Global Chief Operating Officer and Chief Financial Officer. The Global Chief Operating Officer role is a newly created position. Mr. Rao will succeed Naveen Kumar Amar as Chief Financial Officer following Mr. Amar's resignation from the Company for personal reasons. Mr. Rao will be based in the United States and will work closely with the Chairman a

    1/8/26 5:00:00 PM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    SS Innovations Appoints Naveen Kumar Amar as Chief Financial Officer

    FORT LAUDERDALE, Fla., Sept. 26, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Naveen Kumar Amar as the Company's Chief Financial Officer, effective September 24, 2025. Mr. Amar is assuming the Chief Financial Officer role, on a permanent basis, from Dr. Vishwa Srivastava, who has served as the Company's Interim Chief Financial Officer since July 2025. Dr. Vishwa Srivastava will continue in his capacity as the Company's Chief Executive Officer – Asia

    9/26/25 8:30:00 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care

    SS Innovations Announces Chief Financial Officer Transition

    FORT LAUDERDALE, Fla., May 02, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Arvind Palaniappan as the Company's Interim Chief Financial Officer, effective May 1, 2025, pursuant to a planned leadership transition. Anup Sethi, SS Innovations' departing CFO, will remain available to advise the Company prior to the appointment of a permanent CFO.   SS Innovations has commenced a search process to identify and recruit a permanent successor for the CFO role

    5/2/25 8:30:00 AM ET
    $SSII
    Medical/Dental Instruments
    Health Care